NRG Therapeutics

What NRG Therapeutics does

NRG Therapeutics Ltd is a UK-based, clinical-stage drug discovery company developing first-in-class, orally bioavailable, CNS-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) as disease-modifying treatments for neurodegenerative diseases. The company targets two lead indications — amyotrophic lateral sclerosis (ALS/MND) and Parkinson's disease — where no disease-modifying therapies currently exist and where mitochondrial dysfunction is a common underlying pathology. The company's core technology is built around a novel, undisclosed mitochondrially-localized protein regulator ("protein A") that is essential for mPTP opening, enabling differentiated small-molecule inhibition that acts independently of cyclophilin D and overcomes the blood-brain barrier limitation of first-generation mPTP inhibitors such as cyclosporin A.

NRG's lead drug candidate, NRG5051, is a first-in-class oral, CNS-penetrant mPTP inhibitor that demonstrated neuroprotection, reduced neuroinflammation, improved motor function, and lowered neurofilament light chain (NfL) levels in preclinical models of ALS/MND and Parkinson's. The company operates a semi-virtual R&D model, relying on in-house leadership plus outsourced CRO and academic collaborations, and has filed or secured proprietary positions around its small molecule series. NRG5051 commenced a first-in-human Phase 1 randomized, double-blind, combined single and multiple ascending dose trial at CHDR in Leiden, Netherlands, with dosing of first participants in January 2026 and a readout expected by end-2026; the £50M Series B funds subsequent proof-of-concept work in ALS/MND and a Phase 1b in Parkinson's.

The company has no commercial revenue and has been financed to date by a combination of venture capital (Parkinson's UK Virtual Biotech seed funding of ~£2.5M, a £16M Series A led by Omega Funds in November 2022, and a £50M Series B led by SV Health Investors' Dementia Discovery Fund in September 2025) and non-dilutive grants from The Michael J. Fox Foundation (~$6M cumulative including a $5M clinical-enabling grant), Innovate UK (£2.68M), and Target ALS. The stated go-to-market is to develop NRG5051 through proof-of-concept and then partner or license to global pharmaceutical companies for late-stage development and commercialization.

Name

NRG Therapeutics

Legal name

NRG Therapeutics Ltd

Website

https://nrgtherapeutics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

NRG Therapeutics is a UK-based, clinical-stage drug discovery company developing first-in-class, oral, CNS-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) as disease-modifying treatments for ALS/MND and Parkinson's disease. Its lead candidate, NRG5051, entered first-in-human Phase 1 trials in January 2026.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Neurodegenerative disease therapeutics
• Mitochondrial drug discovery
• CNS-penetrant small molecules
• MPTP inhibitors
• ALS Parkinson's drug development

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Development and Commercialization: Pre-commercial biotech company developing disease-modifying mitochondrial therapeutics for neurodegenerative diseases. Revenue model will be based on drug commercialization upon regulatory approval, with potential for licensing/partnerships with global pharma companies for late-stage development and commercialization.
2. Non-dilutive Grant Funding: The company has received multiple non-dilutive grants from foundations (MJFF, Target ALS, Parkinson's UK) and government organizations (Innovate UK) to fund research and development activities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

NRG Therapeutics is a clinical-stage neuroscience drug discovery company developing first-in-class, orally bioavailable, CNS-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases. Its lead drug candidate NRG5051 is being advanced as a disease-modifying treatment for amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) and Parkinson's disease, with a first-in-human Phase 1 clinical trial commenced in January 2026. The company plans to progress NRG5051 through proof-of-concept clinical trials for late-stage development and commercialization by global pharma partners.

Product overview

NRG Therapeutics is a clinical-stage neuroscience drug discovery company developing a pipeline of first-in-class, orally bioavailable, CNS-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases. The company's lead product is NRG5051, a disease-modifying drug candidate targeting ALS/MND (lead indication) and Parkinson's disease. NRG5051 commenced first-in-human Phase 1 clinical trials in early 2026. The company operates a semi-virtual business model with R&D conducted in partnership with global CROs and academic institutions.

Differentiator

Problem solved

Functional benefit

Products and services

• NRG5051 NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed mitochondrially-localized protein regulator. It is being developed as a disease-modifying treatment for ALS/MND (lead indication) and Parkinson's disease, with first-in-human Phase 1 clinical trial initiated in January 2026.

Quantifiable outcome

• Demonstrated neuroprotection and anti-inflammatory effects in in vivo preclinical models of ALS/MND and Parkinson's
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• DomainexcoreTechnology or Integration · 1 June 2022Selected as integrated drug discovery partner for Biomedical Catalyst funded Parkinson's disease project. Domainex provides fully integrated lead optimization services including assay biology and medicinal and computational chemistry.
• WEHI (Walter and Eliza Hall Institute of Medical Research)coreStrategic or Co-development Partner · 1 December 2021Research collaboration with WEHI in Australia, led by Associate Professor Seth Masters, to further drug discovery based on pioneering studies showing that TDP-43 enters mitochondria and triggers mitochondrial DNA release via the mPTP. Professor Masters joined NRG as VP Discovery Biology. This collaboration is funded by FightMND.
• Medicines Discovery CatapultsupportingStrategic or Co-development Partner · 1 November 2021Collaborated with Medicines Discovery Catapult on MND therapeutic analysis project to refine target product profile and understand market opportunity, supported by Innovate UK EDGE grant.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Vanqua Bio: Vanqua Bio is a privately held neuroscience company developing small-molecule activators of glucocerebrosidase (GCase) for Parkinson's disease and other neurodegenerative disorders. Comparable as a CNS-focused biotech pursuing disease-modifying Parkinson's therapies with strong pharma backing.
• Mission Therapeutics: Mission Therapeutics is a UK-based clinical-stage biotech developing small-molecule therapeutics for neurodegenerative and mitochondrial diseases. Highly comparable as a UK-headquartered, CNS-focused biotech with a recent Chief Development Officer who previously served as Mission's CSO.
• Stealth BioTherapeutics: Stealth BioTherapeutics develops mitochondria-targeted therapeutics for diseases involving mitochondrial dysfunction, including neurodegenerative and rare diseases. Direct mechanistic peer to NRG's mPTP-targeting approach in CNS indications.
• Khondrion: Khondrion is a clinical-stage pharmaceutical company developing small-molecule therapies targeting mitochondrial dysfunction for rare diseases and neurodegenerative conditions. Closely comparable mechanism and indication strategy.
• Abliva: Abliva (formerly NeuroVive Pharmaceutical) is a Swedish clinical-stage biotech developing mitochondrial-protective therapies for primary mitochondrial diseases and neurological disorders. Direct competitor in mitochondrial neurotherapeutics.

Broad incumbents

• Denali Therapeutics: Denali Therapeutics is a publicly traded, well-capitalized biotechnology company developing a broad portfolio of therapies for neurodegenerative diseases including Parkinson's and ALS. Larger, more diversified player targeting overlapping indications with greater financial and clinical resources.
• Biogen: Biogen is a major global biotechnology company with an established CNS franchise including Qalsody (tofersen) for ALS. Indirect incumbent in the same therapeutic space with significant commercial and clinical-development capability for neurodegenerative indications.
• Prothena: Prothena is a clinical-stage neuroscience company developing therapies for diseases involving protein misfolding, with active programs in Parkinson's and ALS. Established neurodegenerative-focused biotech with broader pipeline and publicly traded profile.

Emerging players

• Clene Nanomedicine: Clene Nanomedicine is a clinical-stage company developing catalytically active, surface-clean, metallic nanocrystals for neurodegenerative diseases including ALS and MS. Emerging player in CNS disease modification with a differentiated mechanism.
• BioAge Labs: BioAge Labs is a clinical-stage biotech targeting the biology of aging, with metabolic and mitochondrial mechanisms relevant to neurodegenerative and age-related diseases. Thematically adjacent peer focused on mitochondrial and metabolic pathways.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nrgtherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds9 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NRG Therapeutics